Based on the currently available, albeit limited data, efocipegtrutide (HM15211), another GLP-1/GIP/glucagon receptor triple agonist, seems to have beneficial effects in animal models of neurodegenerative diseases [67, 68]
Below 72 hours
This initially included Gus Watanabe, DiMarchii's close mentor and former Chief Scientific Officer at Eli Lilly (Molteni, Chen)
December 19, 2025 4:24 View More Grief Changes Everything The Surprising Routine McCall Uses to Protect Her Energy and Health with McCall McPherson December 11, 2025 2:39 View More Stop Holiday Weight Gain Before It Starts The Ten Science Backed Hacks Every Thyroid Patient Needs with McCall McPherson What if a few simple shifts in how you eat, move, and rest could completely change the way your body handles the holidays
Contact an attorney for advice about your particular situation
The cardiovascular evidence is the most solid: in the SELECT trial, people with obesity and established heart disease who added semaglutide cut their risk of cardiovascular death, a second stroke, or a second heart attack by about 20%
